netFormulary Oxfordshire Clinical Commissioning Group NHS
Formulary  
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
08.01.05  Expand sub section  Other antineoplastic drugs
08.01.05  Expand sub section  Amsacrine
08.01.05  Expand sub section  Arsenic trioxide
08.01.05  Expand sub section  Bexarotene
08.01.05  Expand sub section  Bortezomib to top
08.01.05  Expand sub section  Brentuximab vedotin
08.01.05  Expand sub section  Cetuximab
08.01.05  Expand sub section  Crisantaspase
08.01.05  Expand sub section  Dacarbazine and Temozolomide
08.01.05  Expand sub section  Erlotinib to top
08.01.05  Expand sub section  Hydroxycarbamide
08.01.05  Expand sub section  Imatinab
08.01.05  Expand sub section  Ipilimumab
08.01.05  Expand sub section  Mitotane
08.01.05  Expand sub section  Panitumumab to top
08.01.05  Expand sub section  Pentostatin
08.01.05  Expand sub section  Platinum compounds
08.01.05  Expand sub section  Porfimer sodium and temoporfin
08.01.05  Expand sub section  Procarbazine
08.01.05  Expand sub section  Protein kinase inhibitors to top
Abemaciclib (Verzenios®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
  • For previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in combination with an aromatase inhibitor, as per NICE TA563 (APCO March 2019).
  • With fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy as per NICE TA579 (APCO July 2019). Funded by specialised commissioning. 
 
Link  NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
   
Afatinib (Giotrif®)
View adult BNF View SPC online View childrens BNF
Formulary
NHS England

Red Traffic Light  For treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer as per NICE TA310.

Funded by specialised commissioning.

APCO May 2014.

Black Traffic Light  For treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (Terminated appraisal NICE TA444).

APCO July 2017. 

 
Link  NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Link  NICE TA444: Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
   
Brigatinib (Alunbrig®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

For treating ALK-positive advanced non-small-cell lung cancer after crizotinib as per NICE TA571.

Funded by specialised commissioning.

APCO May 2019.

 
Link  NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
   
Cabozantinib (Cabometyx®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

For treating

  • Previously treated advanced renal cell carcinoma as per NICE TA463 (APCO September 2017).
  • Untreated advanced renal cell carcinoma as per NICE TA542 (APCO November 2018).

Funded by specialised commissioning.

 

 
Link  NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Link  NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
   
Cabozantinib (Cometriq®)
View adult BNF View SPC online View childrens BNF
Formulary
Cancer Drugs Fund
NHS England

Red Traffic Light For treating medullary thyroid cancer, as per NICE TA516.

Funded by specialised commissioning.

APCO May 2018. 

Black Traffic Light Not recommended for previously treated advanced hepatocellular carcinoma as per NICE TA582 (terminated appraisal). 

APCO July 2019.

 
Link  NICE TA516: Cabozantinib for treating medullary thyroid cancer
Link  NICE TA582: Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal)
   
Crizotinib (Xalkori®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

For:

  • Untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer as per NICE TA406 (APCO November 2016).
  • Previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer as per NICE TA422 (APCO January 2017).
  • For treating ROS1-positive advanced non-small-cell lung cancer as per NICE TA529 (APCO September 2018). 

Funded by specialised commissioning.

 
Link  NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Link  NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Link  MHRA: Risk of cardiac failure with crizotinib
   
Dacomitinib  (Vizimpro®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

For untreated EGFR mutation-positive non-small-cell lung cancer as per NICE TA595.

Funded by specialised commissioning. 

APCO September 2019.

 
Link  NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
   
Dasatinib (Sprycel®)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
Cancer Drugs Fund
NHS England

Red Traffic Light  For the treatment of:

  • Imatinib-resistant or intolerant chronic myeloid leukaemia as per NICE TA425.
  • Untreated chronic myeloid leukaemia as per NICE TA426.

Funded by specialised commissioning.

APCO January 2017.

Black Traffic Light  Not recommended for patients with CML resistant to standard dose imatinib or unable to tolerate imatinib as per NICE TA241.

APCO March 2012.

 
Link  NICE TA241: CML where treatment with imatinib has failed
Link  NICE TA425: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Encorafenib (Braftovi®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England
  • For treating unresectable or metastatic BRAF V600 mutation-positive melanoma in combination with binimetinib as per NICE TA562 (APCO March 2019).
  • With Cetuximab for the treatment of colorectal cancer during COVID-19 pandemic as per NICE NG161 (APCO January 2021).

Funded by specialised commissioning.

 
Link  NICE NG161: COVID-19 rapid guideline: delivery of systemic anticancer treatments
Link  NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
   
Entrectinib (Rozlytrek®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England
  • For treating ROS1-positive advanced non-small-cell lung cancer as per NICE TA643.
  • For treating NTRK fusion-positive solid tumours as per NICE TA644.

Funded by specialised commissioning.

APCO September 2020.

 
Link  NICE TA643: Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer
Link  NICE TA644: Entrectinib for treating NTRK fusion-positive solid tumours
   
Cytotoxic Drug Everolimus
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
Cancer Drugs Fund
NHS England

Red Traffic Light  For:

  • Treating advanced breast cancer in combination with exemestane after endocrine therapy as per NICE TA421 (APCO January 2017).
  • Treating advanced renal cell carcinoma after previous treatment as per NICE TA432 (APCO March 2017).
  • Use with sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease as per NICE TA449 (APCO July 2017). 
  • SEGA-TS, agreed at MMTC in October 2018 (APCO November 2018).

Funded by specialised commissioning.

Black Traffic Light  Not recommended for renal transplant patients as per NICE TA481 and TA482.

APCO November 2017.

 
Link  NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Link  NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Link  NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Link  NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
   
Gefitinib (Iressa®)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
NHS England

Red Traffic Light  For the first-line treatment of locally advanced or metastatic non-small-cell lung cancer as per NICE TA192.

Funded by specialised commissioning.

APCO September 2010.

Black Traffic Light  Not recommended for treating non-small-cell lung cancer that has progressed after prior chemotherapy as per NICE TA374.

APCO January 2016.

 
Link  NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Link  NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
   
Gilteritinib (Xospata®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

For treating relapsed or refractory acute myeloid leukaemia as per NICE TA642. 

Funded by specialised commissioning.

APCO September 2020.

 
   
Cytotoxic Drug Imatinib (Gilvec®)
(100mg and 400mg )
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
NHS England

For the treatment of:

  • Gastrointestinal stromal tumours as per NICE TA86 and NICE TA326 (APCO January 2015).
  • Untreated chronic myeloid leukaemia as per NICE TA70 and NICE TA426 (APCO January 2017).
  • Chronic graft versus host disease as per NHS England: 16069/P (APCO September 2017).

Funded by specialised commissioning.

 
Link  NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
Link  NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
Link  NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Link  NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
   
Lenvatinib (Kisplyx®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

With everolimus for previously treated advanced renal cell carcinoma in adults as per NICE TA498.

APCO March 2018.

 
Link  NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
   
Midostaurin (Rydapt®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

Red Traffic Light  For untreated acute myeloid leukaemia as per NICE TA523.

Funded by specialised commissioning.

APCO July 2018.

 
Link  NICE TA523: Midostaurin for untreated acute myeloid leukaemia
   
Nilotinib (Tasigna®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

For the treatment of:

  • Imatinib-resistant or intolerant chronic myeloid leukaemia as per NICE TA425.
  • Untreated chronic myeloid leukaemia as per NICE TA426.

Funded by specialised commissioning.

APCO January 2017.

 
Link  NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Link  NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
   
Nintedanib  (Vargatef®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

For previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer as per NICE TA347.

Funded by specialised commissioning.

APCO September 2015.

 
   
Palbociclib (Ibrance®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England
  • With an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer as per NICE TA495 (APCO January 2018).
  • With fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer as per NICE TA619 (APCO March 2020).

Funded by specialised commissioning.

 

 
Link  NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
   
Pazopanib (Votrient®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

For first-line treatment of advanced renal cell carcinoma as per NICE TA215.

Funded by specialised commissioning.

APCO May 2011.

 
Link  NICE TA215: Pazopanib in renal cell cancer
   
Regorafenib (Stivarga® )
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
Cancer Drugs Fund
NHS England

Red Traffic Light 

  • For previously treated unresectable or metastatic gastrointestinal stromal tumours as per NICE TA488 (APCO January 2018).
  • For previously treated advanced hepatocellular carcinoma as per NICE TA555 (APCO March 2019).

Funded by specialised commissioning.

Black Traffic Light Not recommended for previously treated advanced hepatocellular carcinoma as per NICE TA514. 

APCO May 2018.

 
Link  NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Link  NICE TA514: Regorafenib for previously treated advanced hepatocellular carcinoma
Link  NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
   
Ribociclib (Kisqali®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
NHS England

With an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer as per NICE TA496.

Funded by specialised commissioning.

APCO January 2018.

 
Link  NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
   
Sorafenib (Nexavar®)
View adult BNF View SPC online View childrens BNF
Formulary
High Cost Medicine
Cancer Drugs Fund
NHS England

Red Traffic Light For the treatment of:

  • Advanced hepatocellular carcinoma as per NICE TA474 (APCO November 2017).
  • Differentiated thyroid cancer after radioactive iodine as per NICE TA535 (APCO September 2018).

Funded by specialised commissioning.

Black Traffic Light   Not recommended for:

  • Treatment of advanced hepatocellular carcinoma as per NICE TA189 (APCO July 2010).
  • Treatment of advanced or metastatic renal cell carcinoma (first- and second-line) as per NICE TA178 (APCO September 2009).
 
Link  NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Link  NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
   
Sunitinib (Sutent®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

For the treatment of:

  • Advanced and/or metastatic renal cell carcinoma as per NICE TA169 (APCO July 2009).
  • Gastrointestinal stromal tumours as per NICE TA179 (APCO November 2009).
  • With everolimus for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease ss per NICE TA449 (APCO July 2017). Funded by specialised commissioning. 

 
Link  NICE TA169: Renal cell carcinoma - sunitinib
Link  NICE TA179: Gastrointestinal stromal tumours - sunitinib
Link  NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Link  MHRA: Risk of osteonecrosis of the jaw
   
Tivozanib (Fotivda®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

For treating advanced renal cell carcinoma, in line with NICE TA512. 

Funded by specialised commissioning. 

APCO May 2018. 

 
Link  NICE TA512: Tivozanib for treating advanced renal cell carcinoma
   
Vemurafenib (Zelboraf®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
NHS England

For unresectable or metastatic melanoma with the BRAF V600 mutation as per NICE TA269.

Funded by specialised commissioning.

APCO January 2013.

 
Link  NICE TA269: Vemurafenib for treating malignant melanoma
Link  MHRA: Risk of potentiation of radiation toxicity with vemurafenib
   
08.01.05  Expand sub section  Taxanes
08.01.05  Expand sub section  Topoisomerase I inhibitors
08.01.05  Expand sub section  Trabectedin
08.01.05  Expand sub section  Trastuzumab
08.01.05  Expand sub section  Tretinoin to top
08.01.05  Expand sub section  Vismodegib
 ....
 Non Formulary Items
Alpelisib  (Piqray®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black

Not recommended with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer as per NICE TA652 (terminated appraisal)

APCO November 2020

Link  NICE TA652: Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal)
 
Cytotoxic Drug  Imatinib  (Gilvec®)
(600mg and 800mg)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black
High Cost Medicine

Not recommended for treating imatinib-resistant or intolerant chronic myeloid leukaemia as per NICE TA425.

APCO January 2017.

Link  NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
 
Lapatinib  (Tyverb®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black
High Cost Medicine

Not recommended for in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2 as per NICE TA257.

APCO July 2012.

Link  NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
 
Cytotoxic Drug  Temsirolimus  (Torisel®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black
High Cost Medicine
Cancer Drugs Fund

Not recommended for:

  • Treatment of advanced and/or metastatic renal cell carcinomas per NICE TA178 (APCO September 2009).
  • Treatment of relapsed or refractory mantle cell lymphoma (NICE TA 207 - terminated appraisal). APCO November 2010.

Link  NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
 
Cytotoxic Drug  Vandetanib  (Caprelsa®)

View adult BNF View SPC online View childrens BNF
Non Formulary
Black
High Cost Medicine
Cancer Drugs Fund

Not recommended for treating medullary thyroid cancer as per NICE TA550.

APCO January 2019.

Link  NICE TA550: Vandetanib for treating medullary thyroid cancer
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Red

Red: Medicines which should only be prescribed in secondary care by a specialist.  

Amber Continuation

Amber Continuation: Medicines which should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the GP that the prescribing responsibility has been transferred.   

Amber Shared Care Protocol

Amber Shared Care Protocol: Medicines which are appropriate to be initiated and stabilised by a specialist, once stabilised the medicine may be appropriate for responsibility to be transferred from secondary to primary care with the agreement of a GP and a formal ‘shared care’ agreement. The shared care protocol must be approved by the Area Prescribing Committee Oxfordshire (APCO).   

Green

Green: Medicines which are suitable for initiation and ongoing prescribing within primary care.   

Brown

Brown: Medicines which should only be prescribed in restricted circumstances.  

Black

Black: Medicines which are not recommended for use because of lack of evidence of clinical effectiveness, cost effectiveness or safety.  

OCCG Green

not used  

netFormulary